Your English writing platform
Discover LudwigSuggestions(5)
Exact(11)
Therefore, ovarian cancer patients with KRAS or BRAF mutations may benefit from CI-1040 treatment.
Infants with these genetic mutations may benefit from switching to oral sulfonylurea therapy.
It is possible that cell lines with BRAF and PIK3CA mutations may benefit from the combination.
Notably, several retrospective studies suggested that NSCLC patients with positive HER2 mutations may benefit from HER2-targeted therapy [ 64, 92].
For example, combination therapies to target both oncogenic and TSG mutations may benefit patients within a relevant molecularly defined segment.
On the other hand, a recent data suggested that patients with low-frequency (< 1%) KRAS mutations may benefit of targeted anti-EGFR therapies (Laurent-Puig et al., 2014).
Similar(49)
The findings contradict pre-clinical studies that suggest melanomas with BRAF mutation may benefit from inhibition of dual MEK and PI3K pathway inhibition [ 13, 26].
However, evidence is present that patients harboring the codon 13 c.38 G > A mutation may benefit from anti-EGFR treatment [ 4, 5].
It has been suggested that patients whose tumors harbor a KRAS Gly13Asp mutation may benefit from anti-EGFR mAb therapy [ 20- 22].
These data again raise the possibility that tumours of this phenotype, expressing elevated PLK1 and harbouring TP53 mutation, may benefit from the use of novel PLK1 inhibitors [ 7].
However, as previously mentioned, evidence is now present that patients harboring the codon 13 c.38 G > A mutation may benefit from anti-EGFR treatment [ 4, 5, 14].
More suggestions(15)
mutations may interfere
mutations may sensitize
mutations may be
mutations may result
mutations may represent
mutations may affect
mutations may explain
mutations may disrupt
mutations may find
mutations may cause
mutations may reduce
mutations may identify
mutations may respond
mutations may transform
mutations may vary
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com